Journal
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Volume 98, Issue -, Pages 54-62Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcdb.2019.06.004
Keywords
Non-Small cell lung carcinoma; Cancer metabolism; Mitochondria; Glucose
Categories
Funding
- Ministry of Economy and Competitiveness-MINECO, Spain - FEDER funds/European Regional Development Fund - a way to build Europe [BFU2016-78154-R]
- European Union [766214]
- Department of Health of the Generalitat de Catalunya [SLT006/17/00127]
- AECC Barcelona (Spanish Association Against Cancer Barcelona) [PROYBAR17005NADA]
- Instituto de Salud Carlos III - FEDER funds-a way to build Europe [PI14/01109]
- CERCA Program/Generalitat de Catalunya [2017SGR332, 2017SGR448]
Ask authors/readers for more resources
Lung cancer is the main cause of cancer death worldwide. Non-Small Cell Lung Carcinoma (NSCLC) is the most common subtype of lung cancer, and the prognosis of NSCLC patients in advanced stages is still very poor. Given the need for new therapies, the metabolism of NSCLC has been widely studied in the past two decades to identify vulnerabilities that could be translated into novel anti-metabolic therapeutic approaches. A number of studies have highlighted the role of glucose and mitochondrial metabolism in the development of NSCLC. The metabolic properties of lung tumors have been characterized in detail in vivo, and they include high glucose and lactate use and high heterogeneity regarding the use of nutrients and mitochondrial pathways. This heterogeneity has also been observed in patients infused with labeled nutrients. We will summarize here the knowledge about the use of amino acids, fatty acids and carbohydrates in NSCLC that could lead to new combination treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available